Type 2 Diabetes Mellitus (T2DM)
Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys and nerves. The most common is type 2 diabetes, usually in adults, which occurs when the body becomes resistant to insulin or doesn't make enough insulin. In the past 3 decades the prevalence of type 2 diabetes has risen dramatically in countries of all income levels.
The latest International Diabetes Federation (IDF) Diabetes Atlas (2025) reports that 589 million adults (20-79 years) were living with diabetes in 2024, representing 11.1% - or 1 in 9 - of the adult population. Over 81% adults with diabetes live in low- and middle-income countries. By 2050, our projections show that 1 in 8 adults, approximately 853 million, will be living with diabetes, an increase of 46%.
Type 2 diabetes is the most commonly diagnosed type of diabetes, accounting for over 90% of all cases. The primary indicator of type 2 diabetes is insulin resistance, when the body cannot fully respond to insulin. Factors that contribute to developing type 2 diabetes include being overweight, not getting enough exercise, and genetics. Over time, type 2 diabetes can cause serious damage to the body, especially nerves and blood vessels.
CX11 is an investigational oral small molecule GLP-1 RA designed to address cardiometabolic conditions. GLP-1 RAs have been shown to lower bodyweight, improve insulin sensitivity, and reduce glucose and overall appetite. CX11 aims to overcome limitations of current injectable GLP-1 RAs by offering convenient, once-daily oral administration, and weight reduction comparable to injectable GLP1 RAs. CX11 presents favorable tolerability results, scalability and accessibility as a small molecule product candidate.
In December 2024, CORXEL acquired the worldwide (excluding Greater China) rights to CX11 from Vincentage.
Clinical data from Vincentage’s Phase 2 trial in China demonstrated competitive weight loss with a favorable safety and tolerability profile. CX11 is currently being advanced in a U.S. Phase 2 trial in Obesity, a Global Phase 2 trial in T2DM conducted by CORXEL and being evaluated in a Phase 3 registrational trial in China by Vincentage, positioning it as a potential best-in-class oral therapy for management of obesity and overweight conditions, and T2DM.
Reference:
· World Health Organization (WHO) Diabetes https://www.who.int/news-room/fact-sheets/detail/diabetes
· International Diabetes Federation, Facts and Figures https://idf.org/about-diabetes/diabetes-facts-figures/
· International Diabetes Federation, Type 2 Diabetes, https://idf.org/about-diabetes/types-of-diabetes/type-2/
